On December 17, 2025, the U.S. House of Representatives narrowly approved a highly controversial bill that would criminalize gender‑affirming medical care for minors, including surgeries, puberty blockers, and hormone treatments. The measure, known officially as the Protect Children’s Innocence Act (H.R. 3492), passed 216‑211 in a sharply divided vote that largely split along party lines. Under the proposal, medical providers — and in some circumstances parents or guardians — who knowingly perform or facilitate gender‑affirming care for individuals under 18 could face up to 10 years in federal prison and significant fines if convicted of felony charges. The bill’s passage marked a major escalation in federal action targeting transgender health care, going well beyond state laws that already restrict such treatments in various parts of the country. According to the official summary of H.R. 3492, the bill would amend existing federal criminal law — including provisions tied to female genital mutilation statutes — to encompass gender‑affirming treatments for minors as a punishable offense. Under the text, any procedure or medication intended to change a minor’s physical characteristics to align with a gender different from their “biological sex” would be classified as a federal crime, with exceptions for certain intersex‑related medical treatment. The measure also explicitly forbids arrest or prosecution of individuals receiving such care, focusing criminal penalties on those who provide or facilitate it. By creating a new class of federal criminal offenses for medical providers, the bill intrudes into a policy area traditionally governed by states and medical regulatory bodies, raising questions about federal authority over health care decisions.

The vote underscored the deep partisan polarization surrounding transgender health care politics in the U.S. Republican lawmakers, particularly the bill’s sponsor Rep. Marjorie Taylor Greene (R‑Ga.), argued that the measure was necessary to “protect children from irreversible medical decisions they are too young to make.” Greene touted the vote as fulfilling campaign promises and tied its consideration to broader legislative negotiations, including the must‑pass defense policy bill (NDAA). Most House Republicans backed the bill, framing gender‑affirming care for minors as harmful and ideologically driven, with supporters arguing that puberty blockers and hormone treatments are risks rather than lifesaving care. Nearly all Democrats opposed the measure, asserting that it would replace medical expertise with political ideology and represent an unprecedented federal intrusion into personal medical decisions.

Paragraph 4 — Bipartisan Deviations and Vote Breakdown
While the vote was overwhelmingly partisan, a small number of lawmakers crossed party lines. Three Democrats — Reps. Henry Cuellar and Vicente Gonzalez of Texas and Don Davis of North Carolina — voted with Republicans in favor of the bill, a move that drew attention given its controversial impact Conversely, four Republicans — Reps. Gabe Evans (Colo.), Brian Fitzpatrick (Pa.), Mike Lawler (N.Y.), and Mike Kennedy (Utah) —  These cross‑party votes highlighted some reluctance even within party ranks, though they were not enough to alter the outcome.  Despite passage in the House, the bill is widely expected not to advance in the Senate, where bipartisan support would be required and where it faces strong opposition from Democratic leadership and moderate Republicans.

Civil rights organizations, LGBTQ+ advocacy groups, and medical professionals quickly condemned the House bill as among the most extreme anti‑transgender legislative proposals in U.S. history.  Critics such as the American Civil Liberties Union (ACLU) argued that the bill would have “devastating effects” on transgender youth and families, undermine established medical guidance, and criminalize evidence‑based care that major medical organizations support. They also highlighted troubling language in the bill that could expand criminal prohibitions while endorsing non‑consensual procedures on intersex minors, a point of controversy noted by rights groups. Supporters, meanwhile, emphasized the bill’s framing as a child protection measure, arguing it would prevent minors from undergoing irreversible interventions before they have attained full decision‑making maturity. These conflicting interpretations reflect larger cultural and political battles over transgender rights, the role of government in health care, and parental versus state authority.

The passage of the bill, even if unlikely to become law, marks a significant symbolic victory for conservative lawmakers seeking to codify restrictions on gender‑affirming care at the federal level. It comes amid broader efforts by the Trump administration and aligned policymakers to limit access to such care through executive action and regulatory changes, including proposals to ban federal funding for gender‑affirming treatments under Medicaid and Medicare and to reclassify gender dysphoria in federal policy. Opponents argue these moves could increase stigma, reduce access to care, and exacerbate mental health disparities among transgender youth, a group already shown by health research to face elevated risks without supportive treatment.  As the bill moves — if it does — to the Senate, legal challenges and constitutional questions about federal power over medical decisions are likely to arise, and the debate over transgender health care will continue to play a central role in U.S. political discourse heading into 2026 and beyond